Evidence map›Paper›PMID 26640367›Full record

ArticleDrug design, development and therapy2015

Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma.

Yi-Dan Chen, Zhong-Yuan Liang, Yan-Yan Cen, He Zhang, Mei-Gui Han, Yun-Qiao Tian, Jie Zhang, Shu-Jun Li, Da-Sheng Yang

Abstract read
In one paragraph

Article in Drug design, development and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Tableting of nanoparticle-based formulations for oral delivery: Enhancing biopharmaceutical performance.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026
    Review
  2. State of the art in pediatric nanomedicines.Drug delivery and translational research · 2024
    Review
  3. Review
  4. Article
  5. Nano-enabled agglomerates and compact: Design aspects of challenges.Asian journal of pharmaceutical sciences · 2023
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yi-Dan ChenCollege of Pharmacy, The Third Military Medical University, Chongqing, People's Republic of China.
Zhong-Yuan LiangCollege of Pharmacy, The Third Military Medical University, Chongqing, People's Republic of China.
Yan-Yan CenCollege of Pharmacy, The Third Military Medical University, Chongqing, People's Republic of China.
He ZhangDepartment of Pediatrics, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, People's Republic of China.
Mei-Gui HanDepartment of Pediatrics, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, People's Republic of China.
Yun-Qiao TianDepartment of Pediatrics, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, People's Republic of China.
Jie ZhangDepartment of Pediatrics, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, People's Republic of China.
Shu-Jun LiDepartment of Pediatrics, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, People's Republic of China.
Da-Sheng YangDepartment of Pediatrics, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of the present study was to develop oral dispersible tablets containing prednisolone (PDS)-loaded chitosan nanoparticles using microcrystalline cellulose (MCC 101), lactose, and croscarmellose sodium (CCS). The PDS-loaded chitosan nanoparticles were formulated by ionotropic external gelation technique in order to enhance the solubility of PDS in salivary pH. Prepared nanoparticles were used for the development of oral fast disintegrating tablets by direct compression method. The prepared tablets were evaluated for disintegration time (DT), in vitro drug release (DR), thickness, weight variation, drug content uniformity, friability, and hardness. The effect of concentrations of the dependent variables (MCC, lactose, CCS) on DT and in vitro DR was studied. Fast disintegrating tablets of PDS can be prepared by using MCC, CCS, and lactose with enhanced solubility of PDS. The minimum DT was found to be 15 seconds, and the maximum DR within 30 minutes was 98.50%. All independent variables selected for the study were statistically significant. Oral fast disintegrating tablets containing PDS nanoparticles could be the better choice for the pediatric patients that would result in better patient compliance. From this study, it can be concluded that fast disintegrating tablets could be a potential drug delivery technology for the management of asthma in pediatrics.

Indexed as

Drug Delivery SystemsAdministration, OralAnti-Inflammatory AgentsAsthmaCarboxymethylcellulose SodiumCelluloseChemistry, PharmaceuticalChitosanDrug LiberationExcipientsHardnessHumansHydrogen-Ion ConcentrationLactoseNanoparticlesPrednisoloneAnti-Inflammatory AgentsCarboxymethylcellulose SodiumCelluloseChitosanExcipientsLactosemicrocrystalline cellulosePrednisoloneTabletsANOVAasthmaCCSfactorial designMCCoral tabletsprednisolonesuperdisintegrant

Identifiers

PMID26640367
PMCPMC4662371

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.